Glaxo to pay $15M for diabetes drug milestone
GlaxoSmithKline PLC will give a $15 million milestone payment to Tolerx Inc. because the Cambridge, Mass., company began a late-stage human clinical trial for a new diabetes treatment called otelixizumab.
GlaxoSmithKline PLC will give a $15 million milestone payment to Tolerx Inc. because the Cambridge, Mass., company began a late-stage human clinical trial for a new diabetes treatment called otelixizumab.
The trial will take place at centers in both North America and Europe.
GlaxoSmithKline is based in the United Kingdom but has U.S. headquarters in Philadelphia.
Gene Marks, For The Inquirer
Tracey Tully and Peter Eavis, New York Times
Kim Bhasin, New York Times
Kevin Brasler, Delaware Valley Consumers' Checkbook
Alicia Adamczyk, Washington Post
Julia Carpenter, Washington Post
Kalena Thomhave, Capital & Main
Evan Halper, Washington Post
Associated Press
Jonathan Zimmerman | Columnist
Mike Livingston
Emily Bloch and Max Marin
























